Product Description
ALXN2350 is a gene therapy product consisting of an AAV9 capsid containing BAG3 transgene. (Sourced from: https://clinicaltrials.gov/study/NCT07218887)
Mechanisms of Action: Gene Therapy, BAG3
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Italy, Spain, United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cardiomyopathy, Dilated
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07218887 |
DCMRestore | P2 |
Recruiting |
Cardiomyopathy, Dilated |
2032-01-27 |
12% |
2026-06-17 |
Primary Endpoints|Treatments |
2024-519674-40-00 |
ALXN2350-DCM-201 | P2 |
Not yet recruiting |
Cardiomyopathy, Dilated |
2034-01-01 |
12% |
Recent News Events
Date |
Type |
Title |
|---|